検索画面
細胞材料開発室サイト

戻る 戻る
細胞番号 : 細胞名
RCB2927 : OP9/N-DLL1  update : 2023/10/16
細胞特性(Comment:英)Subline of OP9 cell line, expressing DLL1 and human NGF receptor. See RCB2120 TSt-4/N-DLL1.
細胞特性(日)OP9亜株。DLL1とヒトNGF受容体を発現。RCB2120TSt-4/N-DLL1参照。
細胞特性(寄託者記述:英)
細胞特性(寄託者記述:日)
使用条件(英)Basically, there is no restriction regarding academic use. For commercial use or patent application, please contact Rebirthel Co., Ltd. (info@rebirthel.com).
使用条件(日)学術研究における利用につきましては原則として使用制限はありません。特許等の取得及び商業用途(商業利用)の使用については、リバーセル株式会社(info@rebirthel.com)に問い合わせてください。
備考(英)
備考(日)
提供申込書類(英) Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
提供申込書類(日) 依頼書C-0001.pdf   同意書(非営利学術目的)C-0003.pdf   同意書(営利目的)C-0003p.pdf  
提供同意書は、使用機関の種類や目的に応じて、非営利学術目的 (C-XXXX) と営利目的 (C-XXXXp) の2種類があります。該当する提供同意書をご使用ください(詳細)。特許等の取得及び商業利用等は事前に必ず cellbank.brc@riken.jp までご連絡ください。
提供手数料 手数料とお支払いについてはこちらをご覧ください。
細胞基本情報 寄託者 Kawamoto, Hiroshi
樹立者 Kawamoto, Hiroshi
寄託日 2009
動物種 _mouse < Mammals
動物系統名 B6C3Fe-a/a, op
性別 Unknown
0 day
採取組織 newborn, calvaria
遺伝的特徴 op/op
細胞分類 transformed
遺伝子改変 recombinant
外来遺伝子 MSCV-IRES-NGFR(human),murine DLL1 (delta-like 1)
細胞寿命 infinite
細胞形態 fibroblast-like
Cellosaurus(Expasy) CVCL_B220
細胞培養・検査情報
寄託時情報
ロット情報
培地・試薬情報 培地・試薬一覧はこちらをご覧ください。
培養形態 Adherent cells
培地 MEM ALPHA + 20% FBS
抗生物質 Free
継代方法 0.25% Trypsin
継代密度 1 : 4 split
継代・培地交換頻度 Subculture or Medium Renewal : once/2 days
培養最適温度 37 ℃
二酸化炭素濃度 5 %
凍結培地 Medium + 10% DMSO
凍結方法 Slow freezing
マイコプラズマ (-)
マウス系統検査 OK
アイソザイム検査 LD, NP
画像情報
寄託時情報
ロット情報
文献情報 Reference(英) 2件
Reference(日) 0件
利用者成果(英) 9件
利用者成果(日) 0件

トップへページトップへ
Reference(英)
12338  Raul Vizcardo, Kyoko Masuda, Daisuke Yamada, Tomokatsu Ikawa, Kanako Shimizu, Shin-Ichiro Fujii, Haruhiko Koseki, Hiroshi Kawamoto  Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8(+) T cells  Cell Stem Cell  2013  12(1):31-6  PubMed ID: 23290135   DOI: 10.1016/j.stem.2012.12.006
3312  Miyazaki, Masaki, Kawamoto, Hiroshi, Kato, Yuko, Itoi, Manami, Miyazaki, Kazuko, Masuda, Kyoko, Tashiro, Satoshi, Ishihara, Hiroto, Igarashi, Kazuhiko, Amagai, Takashi, Kanno, Rieko, Kanno, Masamoto  Polycomb group gene mel-18 regulates early T progenitor expansion by maintaining the expression of Hes-1, a target of the Notch pathway.  J Immunol  2005  174:2507-16  PubMed ID: 15728456   DOI: 10.4049/jimmunol.174.5.2507

トップへページトップへ
Reference(日)

トップへページトップへ
利用者成果(英)
19957  Itoh M, Kawagoe S, Nakagawa H, Asahina A, Okano HJ.  Generation of induced pluripotent stem cell (iPSC) from NY-ESO-I-specific cytotoxic T cells isolated from the melanoma patient with minor HLAs: The practical pilot study for the adoptive immunotherapy for melanoma using iPSC technology  Exp Dermatol  2023  32(2):126-134  PubMed ID: 36222007   DOI: 10.1111/exd.14686
21206  Tamaoki N, Siebert S, Maeda T, Ha NH, Good ML, Huang Y, Vodnala SK, Haro-Mora JJ, Uchida N, Tisdale JF, Sweeney CL, Choi U, Brault J, Koontz S, Malech HL, Yamazaki Y, Isonaka R, Goldstein DS, Kimura M, Takebe T, Zou J, Stroncek DF, Robey PG, Kruhlak MJ, Restifo NP, Vizcardo R.  Self-organized yolk sac-like organoids allow for scalable generation of multipotent hematopoietic progenitor cells from induced pluripotent stem cells.  Cell Rep Methods  2023  3(4):100460  PubMed ID: 37159663   DOI: 10.1016/j.crmeth.2023.100460
11382  Nishimura T, Nakauchi H.  Generation of Antigen-Specific T Cells from Human Induced Pluripotent Stem Cells.  Methods Mol. Biol.  2019    PubMed ID: 30649763   DOI: 10.1007/978-1-4939-8938-6_3
14056  Vizcardo R, Rafiqul Islam SM, Maeda T, Tamaoki N, Good ML, Klemen ND, Bosch-Marce M, Jia L, Kruhlak MJ, Restifo NP.  A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants  J Vis Exp  2019  (150)  PubMed ID: 31449236   DOI: 10.3791/58672
14812  Good ML, Vizcardo R, Maeda T, Tamaoki N, Malekzadeh P, Kawamoto H, Restifo NP.  Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells  J Vis Exp  2019  (152)  PubMed ID: 31710026   DOI: 10.3791/59997
10966  Yamada D, Iyoda T, Shimizu K, Sato Y, Koseki H, Fujii SI.  Efficient Production of Functional Human NKT Cells from Induced Pluripotent Stem Cells − Reprogramming of Human Vα24+iNKT Cells  BioProtoc  2017  7  PubMed ID: 34541057   DOI: 10.21769/BioProtoc.2277
7053  Maeda T, Nagano S, Ichise H, Kataoka K, Yamada D, Ogawa S, Koseki H, Kitawaki T, Kadowaki N, Takaori-Kondo A, Masuda K, Kawamoto H.  Regeneration of CD8αβ T Cells from T-cell-Derived iPSC Imparts Potent Tumor Antigen-Specific Cytotoxicity.  Cancer Res.  2016  76:6839-6850  PubMed ID: 27872100   DOI: 10.1158/0008-5472.CAN-16-1149
18709  Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Goto H, Zhu D, Nakayama-Hosoya K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H.  Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation  Cell Stem Cell  2013  12(1):114-26  PubMed ID: 23290140   DOI: 10.1016/j.stem.2012.11.002
6113  Eyrich M, Schreiber SC, Wollny G, Ziegler H, Schlenker R, Koch-Büttner K, Wölfl M, Schlegel PG, Schilbach K. Author information 1 Stem Cell Laboratory, University Children's Hospital Würzburg, Würzburg, Germany. Eyrich_m@klinik.uni-wuerzburg.de Abstract T-cell re-constitution after allogeneic stem cell transplantation (alloSCT) is often dampened by the slow differentiation of human peripheral blood CD34(+) (huCD34(+) ) hematopoietic stem cells (HSCs) into mature T cells. This process may be accelerated by the co-transfer of in vitro-pre-differentiated committed T/NK-lymphoid progenitors (CTLPs). Here, we analysed the developmental potential of huCD34(+) HSCs compared with CTLPs from a third-party donor in a murine NOD-scid IL2Rγ(null) model of humanised chimeric haematopoiesis. CTLPs (CD34(+) lin(-) CD45RA(+) CD7(+) ) could be generated in vitro within 10 days upon co-culture of huCD34(+) or cord blood CD34(+) (CB-CD34) HSCs on murine OP9/N-DLL-1 stroma cells but not in a novel 3-D cell-culture matrix with DLL-1(low) human stroma cells. In both in vitro systems, huCD34(+) and CB-CD34(+) HSCs did not give rise to mature T cells. Upon transfer into 6-wk-old immune-deficient mice, CTLPs alone did not engraft. However, transplantation of CTLPs together with huCD34(+) HSCs resulted in rapid T-cell engraftment in spleen, bone marrow and thymus at day 28. Strikingly, at this early time point mature T cells originated exclusively from CTLPs, whereas descendants of huCD34(+) HSCs still expressed a T-cell-precursor phenotype (CD7(+) CD5(+) CD1a(+/-) ). This strategy to enhance early T-cell re-constitution with ex vivo-pre-differentiated T-lymphoid progenitors could bridge the gap until full T-cell recovery in severely immunocompromised patients after allogeneic stem cell transplantation. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. PMID: 21928276 DOI: 10.1002/eji.201141561 [Indexed for MEDLINE] Free full text Share on FacebookShare on TwitterShare on Google+ Publication type, MeSH terms LinkOut - more resources Supplemental Content Full text links Icon for Wiley Save items View more options Similar articles Charac  Pre-differentiated human committed T-lymphoid progenitors promote peripheral T-cell re-constitution after stem cell transplantation in immunodeficient mice.  Eur J Immunol  2011  41(12):3596-603  PubMed ID: 21928276   DOI: 10.1002/eji.201141561

トップへページトップへ
利用者成果(日)



戻る 戻る 理研トップページへ